Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 11/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 11/20 | 1.00 |
| ▸ | TNF | P01375 | 11/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cdc-801 SCHEMBL9977552 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| Cdc-801 SCHEMBL185853 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637138 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL844824 | 0.93 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637167 | 0.92 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637184 | 0.91 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637242 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637688 | 0.91 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5905221 | 0.91 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637348 | 0.90 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12337065-B2 | Compositions for treating viral infections and methods for same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-06-24 | — | — | US | claimed |
| WO-2024246865-A1 | TRANSPLANT IMMUNOSUPPRESSION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2024-09-26 | — | — | US | claimed |
| EP-4352518-A2 | METHODS OF TREATING CANCER WITH CD-40 AGONISTS | Apexigen America, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117795341-A | Methods of treating cancer using CD-40 agonists | 埃派斯进美国有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| EP-4282413-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-11-29 | — | — | EP | claimed |
| CN-116963773-A | Compositions and methods for treating tumors | 浙江养生堂天然药物研究所有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230338345-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-10-26 | — | — | US | claimed |
| EP-4233870-A2 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | Onco Tracker, Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| EP-4140480-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-03-01 | — | — | EP | claimed |
| WO-2022266496-A1 | METHODS OF TREATING KRAS MUTATION SUBTYPES WITH CD40 AGONIST | PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (US) | 2022-12-22 | — | — | WO | claimed |
| CN-115397411-A | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| WO-2022156727-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | 浙江养生堂天然药物研究所有限公司 | 2022-07-28 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | claimed |
| US-11246876-B2 | Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids | Oncotracker, Inc. (US) | 2022-02-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | PDE4B, PDE4A, PDE4C | PDE4A 2/4885PDE4B 1/4885PDE4C 3/4885 |
| US-20230338345-A1 | DRUG COMBINATION AND USE THEREOF | PDE4B, PDE4A, ADH4 | PDE4A 2/4885PDE4B 1/4885PDE4C 10/4885 |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PDE4A 652/4885PDE4B 394/4885PDE4C 500/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4B 1894/4885PDE4C 1570/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4B 1894/4885PDE4C 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.